Towa Pharma jumps 7% as borrow demand quietly builds

4553 enters the week with an interesting split personality: a strong 7% weekly price gain paired with a lending market that has tightened meaningfully over the same period, suggesting some shorts are quietly pressing the position even as buyers have the upper hand.

The borrow story is the more notable development this week. Availability has dropped to 515% — still comfortable in absolute terms, but down sharply from 974% a month ago and the tightest it has been all year, well below the 52-week high of 1,058%. That tightening has happened in a straight line since late August, as the shares-available-to-borrow pool has nearly halved relative to existing short positions. Cost to borrow remains low at 0.90%, down roughly 20% on the week after a brief spike to 1.13% earlier in September — so while more shorts are building, the borrow market is not yet stressed. The short score, at 40.4, has drifted lower over the past fortnight from a recent high near 41.7, consistent with a market that is reassessing rather than pressing a conviction short.

The price action looks more constructive than the lending data might imply. The stock closed at ¥3,790 on Thursday, up 5.3% on the day and 7.2% on the week — easily outpacing its closest TSE peers. 4540 gained 4.7% on the week and 4502 rose 5.1%, while 4151 added just 2.6%. Towa's relative strength is not a fluke — a recent ORTEX stock score note flagged a 365-day relative strength reading near 88.8, pointing to persistent longer-term outperformance within Japanese pharma. Near-term momentum has been choppier, but this week's move has stabilised that picture.

The most interesting ownership detail is how concentrated this stock remains. Yoshida Jimusho K.K. controls just over 40% of shares, and together with associated entities the Yoshida family circle effectively locks up the majority of the register. That structural illiquidity amplifies any shift in the free float. On the institutional side, Sumitomo Mitsui DS Asset Management added 556,100 shares as of June-end, lifting its stake to 6.5% — one of the more meaningful recent moves on the register. Brown Capital Management trimmed aggressively over the same period, cutting 871,189 shares to leave a residual 2.1% position.

The valuation picture is undemanding. The stock trades at 0.85x book and an EV/EBITDA of 6.7x, with the enterprise value multiple edging up only modestly — roughly 0.16 turns — over the past month. The dividend score ranks in the 90th percentile, though the most recent dividend data on record dates to 2022 and should be treated with caution. The analyst consensus price target of ¥5,250, last updated in late August, implies roughly 38% upside to current levels — a gap wide enough to be interesting, though the data is approaching stale territory at 29 days old.

The next earnings event is pencilled in for November 10. Prior prints have delivered modest one-day moves in both directions — the August 2026 result produced a 2.5% gain on the day before fading over five days, while the most recent print in August saw a small one-day dip then a recovery. With availability continuing to tighten and the stock running near its best levels in months, the dynamic heading into that November date — and whether shorts add further or capitulate — is the data thread worth tracking.